{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(1)"],"submitter":["Umpierrez GE"],"pubmed_abstract":["<b>Background:</b> The association between falls or fall-related fractures and hypoglycemia in people with type 2 diabetes is well established. Insulin treatment is associated with an increased risk of hypoglycemia, which is compounded in people of older age, but the risk is lower with longer-acting vs intermediate- or long-acting basal insulin analogs. <b>Objective:</b> To examine healthcare resource utilization and costs related to falls/fractures in people with type 2 diabetes treated with the longer-acting basal insulin Gla-300 (insulin glargine 300 U/mL) vs long-acting basal insulins (insulin glargine 100 U/mL or insulin detemir)/neutral protamine Hagedorn (NPH). <b>Methods:</b> This retrospective study of Optum's de-identified Clinformatics® Data Mart Database compared data for peopl"],"journal":["Journal of health economics and outcomes research"],"pagination":["171-183"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12043012"],"repository":["biostudies-literature"],"pubmed_title":["Healthcare Resource Utilization and Costs Related to Falls and Fractures Among People With Type 2 Diabetes Receiving Basal Insulin: The FRAGILE Study."],"pmcid":["PMC12043012"],"pubmed_authors":["Li X","Preblick R","Pandya N","Umpierrez GE","Pogge EK","Gill J"],"additional_accession":[]},"is_claimable":false,"name":"Healthcare Resource Utilization and Costs Related to Falls and Fractures Among People With Type 2 Diabetes Receiving Basal Insulin: The FRAGILE Study.","description":"<b>Background:</b> The association between falls or fall-related fractures and hypoglycemia in people with type 2 diabetes is well established. Insulin treatment is associated with an increased risk of hypoglycemia, which is compounded in people of older age, but the risk is lower with longer-acting vs intermediate- or long-acting basal insulin analogs. <b>Objective:</b> To examine healthcare resource utilization and costs related to falls/fractures in people with type 2 diabetes treated with the longer-acting basal insulin Gla-300 (insulin glargine 300 U/mL) vs long-acting basal insulins (insulin glargine 100 U/mL or insulin detemir)/neutral protamine Hagedorn (NPH). <b>Methods:</b> This retrospective study of Optum's de-identified Clinformatics® Data Mart Database compared data for peopl","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-03-13T10:32:57.762Z","creation":"2025-07-08T03:12:26.283Z"},"accession":"S-EPMC12043012","cross_references":{"pubmed":["40309264"],"doi":["10.36469/001c.133274"]}}